Get started
NOVO NORDISK A/SNOVO NORDISK A/SNOVO NORDISK A/S

NOVO NORDISK A/S

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVO/N trade ideas

VCP Breakout Buy in NVONovo Nordisk is emerging from a textbook volatility compression pattern (VCP) - the setup made famous by Mark Minervini. Notice the series of progressively shallower pullbacks from left to right as supply has been absorbed by buyers. NVO is a market-leading stock by all accounts. Shares are up 75% over the last twelve months with no signs of slowing down. This is largely thanks to its new weight loss drug showing tremendous results in clinical trials. The company has also experience accelerating earnings growth for the last several quarters - another favorite quality of Minervini's for identifying top performers. NVO looks buyable here as a swing trade with a stop loss 9-10% below the current price.
NYSE:NVOLong
by rossgivens
1
NVO Novo Nordisk: $195 | The Cure since forever it addresses on major conditions of humans Diabetes Cardio Alzheimer's from acquisition to partnering and continuous r&d this issue is a model to new science and tech companies making it to the next 50 years key is innovation opportunity is wait for major crash to upsize for OG investors or simply appreciate the Business and Leadership behind the company. if you get stuck at fresh highs wait for 5 years to DCA in between the range and sit for 12 years for that life changing gains..
NYSE:NVO
by senyor
Novo Nordisk (NYSE: NVO): Trading Idea for 13/10/2023Pharmaceutical company Novo Nordisk completed its research into the treatment of kidney disease a year ahead of schedule. However, the results will only be published in early 2024. If the company demonstrates convincing positive results, Novo Nordisk's revenue growth prospects will be strong. Today, our focus is on the Novo Nordisk (NYSE: NVO) stock chart. On the D1 timeframe, support has formed at 90.44, with resistance at 93.03, which was broken through on Wednesday 11 October. Quotes surged to their historical maximums. On the H1 timeframe, the short-term target for the price increase is around 110.55, while in the medium term, it could reach 115.30. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:NVO
by RoboMarkets
Novo Nordisk In-depth analysis Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Macroeconomics Fundamental analysis suggests that the US may enter into recession in the near future. Interest rates are currently around 5% and are not expected to fall. US yields are rising, which does not suggest that they will pivot soon. If the US goes into recession, other countries are likely to follow and go into recession as well. This is why it is important to monitor how the NVO performs in a recession. Recession is hitting NVO, but the company is more stable than SP500. Valuation method - Sector analysis The health care sector did not impress last year, but over 5 years it returned 41%, which is an average of 8.2% per year. It is also underperformed against SP500. The large cap sector is doing very well, but low beta is quite disappointing. Valuation Method - relative The company is not the outlier, but it has outperformed most of its peers. PE and other ratios are high, which means the company is overvalued but the market is willing to pay the premium for this stock. Valuation Method - absolute Diabetes is one of the most common causes of death in the world and shortens a human life by an average of 8 years! Anyone with the disease needs immediate treatment. Currently, over 50% of sales of diabetes drugs are generated in the USA, as the American healthcare system is enormously lucrative for producers. The market is growing constantly, and due to increasing affluence and the accompanying poor diet, this will not change in the future. Another trend is not coming from consumers, but from the companies themselves: There are fewer and fewer companies doing research on diabetes. Research is not easy. There are not many big competitors, but new products are regularly coming onto the market that work even better and for longer. So the competition is gradually being squeezed out of the market. The established companies such as Novo Nordisk or Boehringer Ingelheim benefit enormously from this and can further expand their position in the market. Business The business appears to be stable and very profitable. Together with Elly Lilly, NVO has contracts with the US government for its diabetes products. They recently announced a new innovative product - the diabetes pencil, which is already approved in many countries. The company has many production facilities in different countries reducing the foreign exchange risk, which in current situation with high interest rates is very important. R&D pipeline The scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH). The R&D pipeline is pretty big and from the financial statement we see that every year they expand the pipeline. Countries with R&D facilities - 5 "Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities" Employment Leaders have been with the company for a long time, have proven their leadership skills. There are various social programmes to please the employers. Employment is rising year on year. Performance It is very clear from the annual accounts that NVO is doing quite well - sales, turnover and profits are growing. Debt is coming down. They have a diversified asset portfolio that avoids market risk. Dividends Dividends are not so high, but they are increasing every year, which gives us some sense of stability. The payout and coverage ratios are also very good. Ownership There is no lack of institutions investing in this company - Renaissance Technologies, Bank of America Corporation, Morgan Stanley, Blackrock Inc. and others. There are also several mutual fund holders. Consensus rating is "buy", made by several analysts. Technical analysis The market structure is currently bullish. Price is moving in a bullish channel and until this channel holds, NVO should remain "Buy". At the moment, the price is bouncing off the upper band of the channel and appears to be overbought. There is also an imbalance to be closed from the previous impulse move. RSI is suggesting a bullish structure. Valuation method - fair price The fair value models suggest that the company is currently overvalued. According to the VaR, the price could fall to USD 70-80, which is in line with the lower band of the channel and the moving averages. I would say that 70 usd is the fair value for that company, considering all the valuation metrics. Summery Although the stock is overvalued, it seems to have a lot of potential to go up in the future. The business model is very good and stable, and is backed up by the company's accounts. At the moment, all stocks are falling due to the current economic situation, so when the NVO reach the reaction area, we should watch how it will react.
NYSE:NVO
by SerpentForexClub
mean reversion with enhancementsIm looking for mean reversion opportunities in this stock currently. My SL is bassed on time to profit ratio. i dont use stop losses but will get out if theres a 50% decline. I tested for probalistic monthly sharpe ratio outperformance of the s and p 500. I tested for monthly normality with the kolmogrov smirnov statistic. and looked for a non-significant p-value in order to signify the distibution fitting I measured the annual sharpe ratio outperformance. I also measured the uler,calmar,sterling and martin ratio to compare ma drawdown, avg drawdown and loss after previous loss using the ulcer index. I used the hurst exponent to measure if the return distributions are indeed mean reverting then lastly i created a portfolio based around a basket of qualified stocks and maximized its sharpe ratio.
NYSE:NVOLong
by jackypacky
1
Novo is still in an ascending trendMy post is primarily a technical analysis. It is important you understand a technical analysis is a forecast and has a probability, and not a statement that it will be absolutely certain. Fundamental analysts (25) have on Trading View a price target of 1020. There is a wide spread, but most are positive about the stock. Novo is still in an ascending trend as evidenced by the price movements and the moving averages. The price has broken through the resistance at 966, where there is support now. There are two REC, where the big one has an object about 1050 and the small an object about 1030. There is a poor correlation between price peaks and volume peaks. This weakens the trend. RSI just over 50. RSI and OBV do not go up as the price from the beginning of February. From mid-February, the price has divergences to the stochastic oscillator %D. The sum of oscillators and moving averages is from one day to a month on purchase. Considering the stock technically positive for a medium length of time, one to 6 months. Disclaimer: I hold a position in the stock. Remember you need do your own research and assessment before buying and selling. Sources: Trading View
OMXCOP:NOVO_B
by scorpiris
2